Emerging Markets Earnings Roundup: Novartis, Amgen (Part 2)
This article was originally published in PharmAsia News
Novartis executives trumpeted robust growth across most emerging markets, while cautioning a slowdown in China due to the industry-wide compliance probe. For Amgen, a play to expand internationally is said to be paying off though questions remain about its plans for Japan.
You may also be interested in...
The promise of late-stage candidates and emerging markets, where it also disclosed a new deal, was the focus for management on its third quarter earnings call. Underscoring its repositioning as an innovative growth company, Amgen said it will not do further share repurchases in the next few years.
The Swiss drug maker’s executives wouldn’t discuss overall progress of its strategic review under new chairman Joerg Reinhardt on its third quarter conference call, but highlighted the growth of several of its key pharmaceutical products and raised its outlook for 2013 in light of Diovan’s strength.
Amgen is juggling both ends of its strategy, one focused on biosimilars and the other on new R&D-driven products. Further details have emerged about each, as Amgen tries to make the case it's a revenue growth story.